Nanomedicine for the Treatment of Non-Hodgkin Lymphoma by Gandhi, B.Pharm, Tanvi
BU Well 
Volume 4 Health, Wellness, and Life Sciences Clinical Corner 
2019 
Nanomedicine for the Treatment of Non-Hodgkin Lymphoma 
Tanvi Gandhi, B.Pharm 
Butler University 
Follow this and additional works at: https://digitalcommons.butler.edu/buwell 
 Part of the Chemicals and Drugs Commons 
Recommended Citation 
Gandhi, B.Pharm, Tanvi (2019) "Nanomedicine for the Treatment of Non-Hodgkin Lymphoma," BU Well: 
Vol. 4 , Article 10. 
Retrieved from: https://digitalcommons.butler.edu/buwell/vol4/iss1/10 
This Clinical Corner is brought to you for free and open access by Digital Commons @ Butler University. It has been 
accepted for inclusion in BU Well by an authorized editor of Digital Commons @ Butler University. For more 
information, please contact digitalscholarship@butler.edu. 
12 April 2019 
 
Nanomedicine for the Treatment of Non-Hodgkin Lymphoma  
Tanvi Gandhi, B.Pharm 
 
Abstract: Non-Hodgkin lymphoma, or NHL, is the predominant category of lymphoma. NHL is a type of lymphoid hematopoietic 
malignancy which approximately 70,000 Americans are diagnosed with annually, with the number of diagnoses growing annually. For 
decades, chemotherapy was the standard treatment of care, but since the discovery in 1997, monoclonal antibodies are increasingly 
used as an alternate form of therapy. Nonetheless, almost 20,000 Americans succumb to NHL annually, which highlights the 
translational gap between preclinical research and the market. Although a lot of progress has been made in therapy options by 
immunotherapy and combination chemotherapy, the ingenuity of nanomedicine may bridge the translational difficulties while serving 
as a novel form of therapy capable of eradicating solid tumors. The versatility of nanoparticles allows for personalized approach to NHL, 
as opposed to generalized medicine, since the subtypes of lymphoma are pathologically very different from one another. 
EMERGENCE OF NANOMEDICINE 
Non-Hodgkin lymphoma (NHL) affects many Americans 
annually, with a growth of over 5,000 diagnoses in the U.S. 
annually, totaling approximately 75,000 diagnoses in 2018.1,2 
Commonly used treatment options for oncological diseases 
comprise of chemotherapy, radiation, and stem cell 
transplants.2,3 The most common off-target complication for all 
these current therapy alternatives is the death of non-cancerous 
cells due to non-specificity of the treatment used. The 
translational laboratory-to-market pathway is facing a major 
road block due to this adverse effect which in turn undermines 
the efficacy of the original treatment.3 This provides opportunity 
for better suited carriers or a formulation system which will show 
higher efficacy than nonspecific binding of cells.4 In this regard, 
since the discovery in the 1980s, nanoparticles have been rapidly 
conquering the translational medicine sector. There is a growing 
interest in nanomedicine, which is the application of 
nanoparticles for therapeutic purposes.4 Nanoparticles are not 
only making it possible to use newly discovered molecular 
entities in a more suitable formulation but are also bridging the 
time gap between laboratory discovery and patient use. 
Since its introduction in 1974, nanotechnology has rapidly been 
researched, allowing its movement into clinical trials.3 Ever since 
the first FDA approval for Doxil®, an increasing number of phase 
II and phase III clinical trials are now focusing on nanomedicine.4 
The major advantage of using nanoparticles is the versatility in 
size, solubility, and drug loading.5 Based on the desired 
targeting and candidate drug properties, an ideal system can be 
selected as a carrier. Sizes for nanoparticles range from 50 
nanometers to 200 nanometers, where the smaller size helps to 
improve the pharmacokinetic profile of the drug by ensuring it 
stays in the system longer. Drug loading can be improved based 
on hydrophilicity of the drug. More hydrophobic drugs should 
be loaded into nanoemulsions or liposomes while hydrophilic 
drugs are better suited with micelles.5  
Where most formulations struggle with delivery of the drug 
within the cancer cells due to the barrier of penetrating the cell 
membranes, nanoparticles use the process of endocytosis or cell 
membrane fusion for cell internalization.6,7 Although 
endocytosis is the more prevalent of the two methods, there are 
still issues with insufficient drug release due to endosomal 
escape or degradation by lysosomes.8 Cell membrane fusion is 
a mechanism proposed to be used particularly by liposomes, 
wherein the similarity in phospholipid composition of cell mem-
brane and liposomal membrane causes the membranes to fuse.8 
Newer targeting mechanisms involve the use of stimuli-
response release, which may be based on temperature, pH, light, 
or enzymes.6,7 
Due to the advancement and increasing success of 
nanomedicine in cancer, scientists are applying the same 
principles of nanoparticles to the research in the fields of other 
chronic illnesses like diabetes and cardiovascular disease.9 
Engineered nanoparticles have unlocked new avenues by not 
only providing sophisticated treatment options but also giving 
us access to early diagnosis of various cancers. The diagnostic 
capabilities combined with the therapeutic power has enabled 
nanoparticles to be designed with target specificity, thereby 
reducing the off-target adverse effects.9 Table 1 highlights the 
nanoparticulate formulations currently approved by the FDA on 
the market. 
 
CHALLENGES IN CLINICAL TRANSITION  
Clinical translation of nanomedicine is not only expensive but 
also a very time-intensive process. From a formulation aspect, it 
is harder to manufacture nanoparticles with the same 
reproducibility and quality as the traditional forms of medicine, 
such as tablets, injectables, and suspensions.9,10 There are several 
factors, including cancer pathophysiology, manufacturing scale-
up, toxicology profile, and biocompatibility, which pose as 
market barriers, irrespective of the increasing number of pre-
clinical research articles being published.11,12 
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Drug  Formulation Indication(s) Manufacturer FDA approval 
date  
Oncaspar PEG-asparaginase ALL Sigma-Tau 
Pharmaceuticals 
1994 
Doxil/Caelyx Pegylated liposomal 
doxorubicin 
Ovarian cancer, multiple myeloma and 
AIDs-related Kaposi’s sarcoma  
Janssen-Cilag 
International  
1995 
DuanoXome  Liposomal daunorubicin Advanced HIV-related Kaposi’s sarcoma  Galen US  1996  
DepoCyt  Liposomal cytarabine Lymphomtous meningitis Pacira 
Pharmaceuticals  
1999 
Myocet Liposomal doxorubicin Metastatic breast cancer  Teva 
Pharmaceuticals  
2000 
Abraxane Albumin-bound 
paclitaxel nanospheres 
Metastatic pancreatic cancer and other 
related cancers  
Celgene  2005  
Genexol-PM Pacitaxel loaded 
polymeric micelle  
Metastatic breast cancer and NSCLC  Samyang  2007 (in Korea)  
Marqibo Liposomal vincristine 
sulphate  
Philadelphia chromosome-negative 
lymphoblastic leukemia 
Talon therapeutics  2012  
TABLE 1: FDA approved nanoparticle formulations for cancer (NSCLC: Non-small cell lung cancer; ALL: Acute lymphoblastic leukemia)8 
TYPES OF NANOCARRIERS  
Although most of the nanoparticle products on the market 
comprise of liposomes as the nanocarrier, polymers and some 
metals are now being used in the formulation as well.13,14 The 
choice of the carrier is crucial to efficacy of the formulation and 
depends largely on the therapeutic material to be encapsulated. 
For instance, delivery of siRNA demands high endosomal 
escape, hence a carrier with that ability must be designed.13 
Choice of vehicle has an impact on the ADME profile of the final 
product and each carrier has its own merits and pitfalls. 
Nanoparticles may be broadly classified as rigid, such as 
polymeric and inorganic nanoparticles, or non-rigid, such as 
liposome, micelle and solid lipid nanoparticle. Another form of 
classification divides them into organic nanoparticles, including 
micelle, liposome, nanogel and dendrimer, and inorganic 
nanoparticles, including SPIONs, gold nanoparticles, quantum 
dot nanoparticles and paramagnetic lanthanide ions.13 
 
CONCLUSION AND FUTURE SCOPE  
Although over 5% of newly diagnosed cancers are categorized 
as NHL, not many chemotherapeutic regimens are approved by 
the FDA to improve the patient survival and quality of life.13 
Immunotherapy has greatly improved the NHL outcomes, but 
the prognosis of NHL remains poor as compared to other 
cancers.15 The introduction of nanotherapeutics might 
revolutionize the NHL market by providing better tolerance for 
the current drugs while obtaining the desired cytotoxicity for 
cancer cells. Currently, five different types of nanoparticles are 
being investigated in clinical trials.15 
Moving forward, identifying and overcoming the crucial 
challenges will help NHL-directed nanomedicine to evolve and 
reach the market. Some of these challenges include targeting 
and selectivity, making it able to move beyond the EPR 
(enhanced permeability and retention) effect.16 Nanoparticles 
can be engineered to target a ligand as well as encapsulate 
molecular targeting agents. In addition to delivering 
encapsulated drugs, nanoparticles can be used to effectively 
deliver nucleic acids, antibodies and other genetic materials.16 
Another challenge in developing anti-lymphoma nano-
therapeutics is the translation from lab to market. Very few of 
the formulations which work in vivo translate those results in 
humans since the physiologies of the two species are different.16 
For clinical trials, the enrolment is a lengthy process and most of 
the subjects are patients who have failed to respond to the 
standard of care treatments. Taking into consideration the out-
come of this disease in the absence of medicine, blinding of 
clinical trials would be unethical and could lead to a further 
reduction in the trial participation. More recently, canine clinical 
trials are being conducted with dogs which naturally contracted 
NHL.16 Since disease progression is faster in dogs, the time for 
clinical trials is also relatively reduced.15 
In the future, nanomedicine synthesized using lipids, polymers 
and chemotherapeutic drugs will play an important role in the 
treatment regimen for NHL. Coupling the recent and exciting 
discovery of CRISPR-Cas9 with nanoparticles would serve as a 
powerful permanent genetic manipulation tool allowing 
mutations and correction of translocations.16,17 Since the vast 
majority of NHL arises due to genetic aberrations, such as mantle 
cell lymphoma, the disease could be a perfect target for this new 
technology.17 This system could also have advantages over some 
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of the other commonly used nucleic acids, including siRNA and 
DNA.17 
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